{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:26:10Z","timestamp":1790623570676,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd011612","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,9,23]],"date-time":"2015-09-23T00:00:00Z","timestamp":1442966400000}}],"reference-count":232,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011612.pub2","type":"journal-article","created":{"date-parts":[[2015,9,23]],"date-time":"2015-09-23T12:49:54Z","timestamp":1443012594000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Ketamine and other glutamate receptor modulators for depression in adults"],"prefix":"10.1002","author":[{"given":"Caroline","family":"Caddy","sequence":"first","affiliation":[{"name":"University of Oxford; Department of Psychiatry; Warneford Hospital Oxford UK OX3 7JX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben H","family":"Amit","sequence":"additional","affiliation":[{"name":"Tel Aviv University; Department of Psychiatry, Sackler Faculty of Medicine; Tel Aviv Israel"},{"name":"Geha Mental Health Center; Research Unit; Petach Tiqva Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayla L","family":"McCloud","sequence":"additional","affiliation":[{"name":"University of Oxford; Department of Psychiatry; Warneford Hospital Oxford UK OX3 7JX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M","family":"Rendell","sequence":"additional","affiliation":[{"name":"University of Oxford; Department of Psychiatry; Warneford Hospital Oxford UK OX3 7JX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshi A","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Kyoto University Graduate School of Medicine \/ School of Public Health; Department of Health Promotion and Human Behavior; Yoshida Konoe-cho, Sakyo-ku, Kyoto Japan 606-8501"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert","family":"McShane","sequence":"additional","affiliation":[{"name":"University of Oxford; Radcliffe Department of Medicine; John Radcliffe Hospital Level 4, Main Hospital, Room 4401C Oxford Oxfordshire UK OX3 9DU"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Hawton","sequence":"additional","affiliation":[{"name":"Warneford Hospital; Centre for Suicide Research, University Department of Psychiatry; Oxford UK OX3 7JX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cipriani","sequence":"additional","affiliation":[{"name":"University of Oxford; Department of Psychiatry; Warneford Hospital Oxford UK OX3 7JX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,9,23]]},"reference":[{"key":"10.1002\/14651858.CD011612.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4088\/JCP.13m08454","article-title":"The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial","volume":"75","author":"Berk","year":"2014","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.psychres.2013.12.008","article-title":"Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder","volume":"215","author":"Ghasemi","year":"2013","journal-title":"Psychiatry Research"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jad.2006.03.004","article-title":"Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder","volume":"93","author":"Heresco-Levy","year":"2006","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1017\/S1461145712000910","article-title":"A Randomized add-on trial of high-dose d-cycloserine for treatment-resistant depression","volume":"16","author":"Heresco-Levy","year":"2013","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"10","key":"10.1002\/14651858.CD011612.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.biopsych.2013.02.020","article-title":"Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression","volume":"74","author":"Huang","year":"2013","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/npp.2011.338","article-title":"Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs Add-on riluzole: Results from a 4-week, double-blind, placebo-controlled study","volume":"37","author":"Ibrahim","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/JCP.0b013e31825d70d6","article-title":"A randomized, placebo-controlled crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder","volume":"32","author":"Ibrahim","year":"2012","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/YCT.0b013e318283b7e9","article-title":"Effects of S-ketamine as an anesthetic adjuvant to propofol on treatment response to electroconvulsive therapy in treatment-resistant depression: A randomized pilot study","volume":"29","author":"Jarventausta","year":"2013","journal-title":"Journal of ECT"},{"issue":"12","key":"10.1002\/14651858.CD011612.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.biopsych.2014.03.026","article-title":"A randomized controlled trial of intranasal ketamine in major depressive disorder","volume":"76","author":"Lapidus","year":"2014","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jad.2012.04.032","article-title":"Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial","volume":"142","author":"Loo","year":"2012","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"582","DOI":"10.4088\/JCP.v68n0414","article-title":"Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study","volume":"68","author":"Michelson","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD011612.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/npp.2014.298","article-title":"Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial","volume":"40","author":"Murrough","year":"2015","journal-title":"Neuropsychopharmacology."},{"key":"10.1002\/14651858.CD011612.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial","volume":"170","author":"Murrough","year":"2013","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/da.22253","article-title":"Effects of ketamine on explicit and implicit suicidal cognition: A randomized controlled trial in treatment-resistant depression","volume":"31","author":"Price","year":"2014","journal-title":"Depression and Anxiety"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1177\/0269881112458728","article-title":"Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: An exploratory, randomized, double-blind, placebo-controlled trial","volume":"26","author":"Nations","year":"2012","journal-title":"Journal of psychopharmacology"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1177\/0269881112458728","article-title":"Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: An exploratory, randomized, double-blind, placebo-controlled trial","volume":"26","author":"Nations","year":"2012","journal-title":"Journal of psychopharmacology"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0018|cit18","first-page":"525","article-title":"Memantine add on to citalopram in elderly patients with depression: A double-blind placebo-controlled study","volume":"19","author":"Omranifard","year":"2014","journal-title":"Journal of Research in Medical Sciences"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/JCP.0b013e31818a6cea","article-title":"An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder","volume":"28","author":"Preskorn","year":"2008","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"9","key":"10.1002\/14651858.CD011612.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/mp.2013.130","article-title":"Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects","volume":"19","author":"Sanacora","year":"2014","journal-title":"Molecular Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD011612.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/mp.2013.130","article-title":"Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects","volume":"19","author":"Sanacora","year":"2014","journal-title":"Molecular Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"966","DOI":"10.4088\/JCP.12m08252","article-title":"Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: A randomized, double-blind, placebo-controlled trial","volume":"74","author":"Smith","year":"2013","journal-title":"Journal of Clinical Psychiatry Diseases of the Nervous System"},{"issue":"4","key":"10.1002\/14651858.CD011612.pub2-BIB0023|cit23","first-page":"287","article-title":"Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression","volume":"34","author":"Sos","year":"2013","journal-title":"Neuro Endocrinology Letters"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/YCT.0b013e3182a4b4c6","article-title":"Comparing effects of ketamine and thiopental administration during electroconvulsive therapy in patients with major depressive disorder: A randomized, double-blind study","volume":"30","author":"Yoosefi","year":"2014","journal-title":"Journal of ECT"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1176\/appi.ajp.163.1.153","article-title":"A double-blind, placebo-controlled study of memantine in the treatment of major depression","volume":"163","author":"Zarate","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.biopsych.2012.10.019","article-title":"A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression","volume":"74","author":"Zarate","year":"2013","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.biopsych.2009.08.038","article-title":"Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression","volume":"67","author":"aan het Rot","year":"2010","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/YCT.0b013e31824f8296","article-title":"Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting","volume":"28","author":"Abdallah","year":"2012","journal-title":"Journal of ECT"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1002\/jnr.22444","article-title":"The decade of the dendritic NMDA spike","volume":"88","author":"Antic Srdjan","year":"2010","journal-title":"Journal of Neuroscience Research"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1089\/cap.2004.14.593","article-title":"The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: A retrospective chart review","volume":"14","author":"Barzman","year":"2005","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1017\/S1461145799001686","article-title":"Fluoxetine augmentation in citalopram non-responders: Pharmacokinetic and clinical consequences","volume":"3","author":"Bondolfi","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.biopsych.2012.03.029","article-title":"Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression","volume":"72","author":"Cornwell","year":"2012","journal-title":"Biological Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD011612.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/00004714-200004000-00029","article-title":"Pramipexole augmentation of a selective serotonin reuptake inhibitor in the treatment of depression","volume":"20","author":"DeBattista","year":"2000","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"7","key":"10.1002\/14651858.CD011612.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1176\/appi.ajp.2011.11010128","article-title":"Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation","volume":"168","author":"Denk","year":"2011","journal-title":"The American Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD011612.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/npp.2012.248","article-title":"Connecting inflammation with glutamate agonism in suicidality","volume":"38","author":"Erhardt","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.euroneuro.2012.07.006","article-title":"Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR*D","volume":"23","author":"Fabbri","year":"2013","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4088\/JCP.v62n0106","article-title":"Reemergence of sexual dysfunction in patients with major depressive disorder: double-blind comparison of nefazodone and sertraline","volume":"62","author":"Ferguson","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0039|cit39","unstructured":"Furey M Drevets W Khanna A Zarate C Differences in response to implicit emotional faces in anterior cingulate cortex predict antidepressant response to scopolamine in major depressive disorder abstract Biological Psychiatry. Abstracts of the 67th Annual Scientific Convention and Meeting of the Society of Biological Psychiatry; 2012 May 3-5; Philadelphia, (PA) 2012"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.biopsych.2013.12.010","article-title":"Long-lasting effects of a single subcutaneous dose of Ketamine for treating melancholic depression: A case report","volume":"76","author":"Galvez","year":"2014","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1176\/appi.ajp.2009.08081167","article-title":"Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder","volume":"167","author":"Garriock","year":"2010","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2014.09.005","article-title":"Fast BDNF serum level increase and diurnal BDNF oscillations are associated with therapeutic response after partial sleep deprivation","volume":"59","author":"Giese","year":"2014","journal-title":"Journal of Psychiatric Research"},{"issue":"1","key":"10.1002\/14651858.CD011612.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"49","DOI":"10.12740\/PP\/20566","article-title":"Effectiveness of ketamine in depressed patients resistant to ECT or rTMS therapy","volume":"48","author":"Gosek","year":"2014","journal-title":"Psychiatria Polska"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0044|cit44","first-page":"772","article-title":"Ketamine for the treatment of depression: what about the addictive potential?","volume":"41","author":"Hillemacher","year":"2007","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"658","DOI":"10.4088\/JCP.v66n0519f","article-title":"Development of subtle psychotic symptoms with memantine: A case report 4 [letter]","volume":"66","author":"Huey","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.pnpbp.2011.03.019","article-title":"Rapid decrease in depressive symptoms with an N-methyl-D-aspartate antagonist in ECT-resistant major depression","volume":"35","author":"Ibrahim","year":"2011","journal-title":"Progress in Neuro-psychopharmacology and Biological Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1089\/jpm.2010.9808","article-title":"Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care","volume":"13","author":"Irwin","year":"2010","journal-title":"Journal of Palliative Medicine"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0048|cit48","unstructured":"Janssen Research Development L L C An Exploratory, Blinded, Randomized, Placebo-controlled Study in Subjects With Depressive Disorder to Investigate the Effect of Minocycline on Relapse After Successful Intravenous Ketamine\/Minocycline-induced (Partial) Symptoms Response http:\/\/clinicaltrials.gov\/show\/NCT01809340 2013"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"S320","DOI":"10.1016\/S0924-977X(13)70503-0","article-title":"Improvement in subjective and objective neurocognitive functions in patients with major depressive disorder: Tianeptine versus escitalopram","volume":"Conference: 26t","author":"Jeon","year":"2013","journal-title":"European neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0050|cit50","unstructured":"Kaddurah-Daouk R Pharmacometabolomic analysis of depression and treatment outcomes abstract Biological psychiatry [abstracts of the 68th Annual Scientific Convention and Meeting of the Society of Biological Psychiatry, SOBP; 2013 May 16-18; San Francisco, CA United States] 2013 107S 8S"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40263-013-0075-9","article-title":"Loxapine inhalation powder: A review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia","volume":"27","author":"Keating","year":"2013","journal-title":"CNS drugs"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0052|cit52","first-page":"170","article-title":"Ketamine followed by memantine for the treatment of major depression","volume":"42","author":"Kollmar","year":"2008","journal-title":"Australian and New Zealand journal of psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/01.chi.0000169012.81536.38","article-title":"Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms","volume":"44","author":"Kratochvil","year":"2005","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1017\/S1461145711000629","article-title":"A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department","volume":"14","author":"Larkin","year":"2011","journal-title":"International journal of neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1080\/15622970701420481","article-title":"Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression","volume":"10","author":"Liebrenz","year":"2009","journal-title":"World journal of biological psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/j.jpsychires.2013.08.021","article-title":"A new early cognitive screening measure to detect cognitive side-effects of electroconvulsive therapy?","volume":"47","author":"Martin","year":"2013","journal-title":"Journal of psychiatric research"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.psychres.2010.07.039","article-title":"Serotonin transporter polymorphism as a predictor for escitalopram treatment of major depressive disorder comorbid with alcohol dependence NCT00368862","volume":"186","author":"Muhonen","year":"2011","journal-title":"Psychiatry research"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1440-1614.2004.01328.x","article-title":"Refractory pain-depression syndrome treated with tianeptine: A case report","volume":"38","author":"Muniz Paulo","year":"2004","journal-title":"Australian and New Zealand journal of psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0059|cit59","unstructured":"NCT00826111 The effects of eszopiclone and lexapro on prefrontal glutamate and GABA in depression with co-morbid anxiety and insomnia: a proton MRS Study https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00826111"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1017\/S1092852900015716","article-title":"Unexpected reduction in migraine and psychogenic headaches following rTMS treatment for major depression: a report of two cases","volume":"12","author":"O'Reardon","year":"2007","journal-title":"CNS spectrums"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1468-1331.2004.00976.x","article-title":"Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors","volume":"12","author":"Omdal","year":"2005","journal-title":"European journal of neurology"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1176\/appi.ajp.2007.06111790","article-title":"Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort","volume":"164","author":"Paddock","year":"2007","journal-title":"American journal of psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/01.jcp.0000203228.64117.9f","article-title":"Visual Hallucinations from the Addition of Riluzole to Memantine and Bupropion","volume":"26","author":"Pittenger","year":"2006","journal-title":"Journal of clinical psychopharmacology"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0064|cit64","first-page":"No","article-title":"The involvement of sigma receptor modulation in the antidepressant effects of ketamine and the neurotoxic actions of methamphetamine","volume":"75","author":"Robson Matthew","year":"2014","journal-title":"Dissertation abstracts international: section b: the sciences and engineering dissertation abstracts international"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/JCP.0000000000000068","article-title":"An open-label, pilot study evaluating the safety and antidepressant effects of rellidep in major depressive disorder","volume":"34","author":"Sadavoy","year":"2014","journal-title":"Journal of clinical psychopharmacology"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jpsychires.2012.04.004","article-title":"Pilot study of the efficacy of double-blind, placebo-controlled one-week olanzapine stabilization therapy in heterogeneous symptomatic bipolar disorder patients","volume":"46","author":"Srivastava","year":"2012","journal-title":"Journal of psychiatric research"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/ICO.0b013e31823f8af4","article-title":"Ketamine-associated corneal edema","volume":"31","author":"Starte","year":"2012","journal-title":"Cornea"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jad.2012.10.015","article-title":"A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression","volume":"147","author":"Szymkowicz Sarah","year":"2013","journal-title":"Journal of affective disorders"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1471-244X-12-37","article-title":"Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features","volume":"12","author":"Tsutsui","year":"2012","journal-title":"BMC psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/jppr2002323212","article-title":"Ketamine as a possible cause of delirium","volume":"32","author":"Wein","year":"2002","journal-title":"Journal of pharmacy practice and research"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0071|cit71","unstructured":"Weintraub D Mavandadi S Horn S Siderowf A Duda J Stern M Atomoxetine for the treatment of depression in Parkinson's disease: a randomised, double-blind, placebo-controlled study meeting abstract American Journal of Geriatric Psychiatry [abstracts from the 14th Annual Meeting of the American Association of Geriatric Psychiatry (AAGP), Honolulu, Hawai'i, 5-8 March 2009] 2009"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1517\/14740338.3.5.495","article-title":"Safety and side effect profile of fluoxetine","volume":"3","author":"Wernicke","year":"2004","journal-title":"Expert opinion on drug safety"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/11204340-000000000-00000","article-title":"Escitalopram: In the treatment of major depressive disorder in adolescent patients","volume":"12","author":"Yang","year":"2010","journal-title":"Pediatric Drugs"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0074|cit74","first-page":"177","article-title":"Clinical Impact of CYP2D6 Activity in Long-term Paroxetine Treatment","volume-title":"New developments in anxiety disorder research","author":"Zourkova","year":"2006"},{"issue":"12","key":"10.1002\/14651858.CD011612.pub2-BIB0075|cit75","first-page":"912","article-title":"Mental confusion due to the administration of tramadol in a patient treated with MAOI [French]","volume":"54","author":"Calvisi","year":"1999","journal-title":"Revue Medicale de Liege"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/YCT.0b013e3182801b09","article-title":"Augmenting transcranial direct current stimulation with (D)-cycloserine for depression: a pilot study","volume":"29","author":"Chan","year":"2013","journal-title":"Journal of ECT"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0077|cit77","first-page":"145","article-title":"Treatment-refractory depression: A case of successful treatment with intranasal ketamine 10%","volume":"26","author":"Clark","year":"2014","journal-title":"Annals of Clinical Psychiatry"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011612.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"S453","DOI":"10.1016\/S0924-977X(14)70726-6","article-title":"Efficacy and safety of a novel mGlu2 receptor positive allosteric modulator as an adjunctive treatment in anxious depression","volume":"24","author":"Daly","year":"2014","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1345\/aph.1D344","article-title":"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine","volume":"38","author":"Houlihan","year":"2004","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0080|cit80","unstructured":"IRCT201104092266N2 Comparison of the effect of electroconvulsive therapy and intravenous infusion of ketamine on control and relapse of depressive symptoms in depressive cases who are candidates of electro convulsive therapy http:\/\/www.irct.ir\/searchresult.php?id=2266&number=2"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0081|cit81","unstructured":"ISRCTN14689382 Ketamine augmentation of ECT to improve outcomes in depression http:\/\/isrctn.org\/ISRCTN14689382"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0082|cit82","unstructured":"ISRCTN87057460 Effectiveness of the dual serotonin norepinephrine reuptake inhibitor venlafaxine in depressed patients http:\/\/www.isrctn.com\/ISRCTN87057460"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.5694\/j.1326-5377.1972.tb108067.x","article-title":"A comparison of ketamine and methohexital in electroconvulsive therapy","volume":"1","author":"McInnes","year":"1972","journal-title":"Medical Journal of Australia"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0084|cit84","unstructured":"NCT01046630 A Phase I, multi-centre, double-blind, placebo-controlled parallel group study to assess the pharmacoMRI effects of AZD6765 in male and female subjects fulfilling the criteria for major depressive disorder http:\/\/clinicaltrials.gov\/show\/NCT01046630"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0085|cit85","unstructured":"NCT01306760 The use of ketamine as an anaesthetic during electroconvulsive therapy (ECT) for depression: does it improve treatment outcome? http:\/\/clinicaltrials.gov\/show\/NCT01306760"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0086|cit86","unstructured":"NCT01482221 A multicenter, randomized, double-blind, parallel group, placebo-controlled, phase IIb efficacy and safety study of adjunctive AZD6765 in patients with major depressive disorder (MDD) and a history of inadequate response to antidepressants study D6702C00031 http:\/\/clinicaltrials.gov\/show\/NCT01482221"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0087|cit87","unstructured":"NCT01627782 A double-blind, randomized, placebo-controlled, parallel group, dose frequency study of ketamine in subjects with treatment-resistant depression http:\/\/clinicaltrials.gov\/show\/NCT01627782"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011612.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0924-9338(13)77083-4","article-title":"A phase ii randomized, double-blind, placebo-controlled trial of GLYX-13 for the rapid treatment of major depressive disorder using central ratings [abstract]","volume":"28","author":"Popp","year":"2013","journal-title":"European Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.psychres.2013.12.027","article-title":"A randomized comparison of ketamine versus methohexital anesthesia in electroconvulsive therapy","volume":"215","author":"Rasmussen","year":"2014","journal-title":"Psychiatry Research"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0090|cit90","doi-asserted-by":"crossref","unstructured":"Ruiz-Chow A Ramirez-Bermudez J Alviso-de la Serna L Rios C Amantadine: A treatment for major depressive disorder conference [abstract] European Neuropsychopharmacology. Proceedings of the 23rd European College of Neuropsychopharmacology (ECNP) Congress; 2010 Aug 28-Sept 01; Amsterdam 2010 S352","DOI":"10.1016\/S0924-977X(10)70488-0"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0091|cit91","unstructured":"Singh J Fedgchin M Daly E Xi L Melman C De Bruecker G Efficacy and safety of intravenous esketamine in patients with treatment-resistant depression: A double-blind, double-randomization, placebo controlled phase 2a study abstract Neuropsychopharmacology. Abstracts of the 52nd Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2013 Dec 8-12; Hollywood, FL 2013 S369 70"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0092|cit92","unstructured":"Singh J Fedgchin M Daly E De Boer P Cooper K Lim P A double-blind, randomized, placebo-controlled, parallel group, dose frequency study of intravenous ketamine in patients with treatment-resistant depression abstract Biological Psychiatry. Abstracts of the 69th Annual Scientific Convention and Meeting of the Society of Biological Psychiatry, SOBP; 2014 May 8-10; New York, NY 2014 44S"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0093|cit93","unstructured":"EUCTR2011-001520-37-SE Ketamine as an alternative to electroconvulsive therapy for treatment of major depressive disorder https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=Vestibular+Disorders"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0094|cit94","unstructured":"EUCTR2011-005476-41-GB Ketamine augmentation of ECT to improve outcomes in depression - Ketamine-ECT study https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005476-41\/GB"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0095|cit95","unstructured":"IRCT201307181556N54 Riluzole as adjuvant therapy in the treatment of moderate to severe major depression: A double - blind placebo-controlled trial http:\/\/www.irct.ir\/searchresult.php?keyword=&id=1556&number=54&prt=5237&total=10&m=1"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0096|cit96","unstructured":"NCT00988663 Memantine augmentation of electroconvulsive therapy in patients with major depression http:\/\/clinicaltrials.gov\/show\/NCT00988663"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0097|cit97","unstructured":"NCT01179009 A safe ketamine-based therapy for treatment resistant depression http:\/\/clinicaltrials.gov\/show\/NCT01179009"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0098|cit98","unstructured":"NCT01204918 Efficacy and tolerability of riluzole in treatment resistant depression http:\/\/clinicaltrials.gov\/show\/NCT01204918"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0099|cit99","unstructured":"NCT01260649 N-methyl-D-aspartate antagonist (ketamine) augmentation of electroconvulsive treatment for severe major depression http:\/\/clinicaltrials.gov\/show\/NCT01260649"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0100|cit100","unstructured":"NCT01441505 A study of ketamine as an antidepressant http:\/\/clinicaltrials.gov\/show\/NCT01441505"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0101|cit101","unstructured":"NCT01557712 Estimate the efficiency of the association of an injection of ketamine and the venlafaxine in the severe major depressive disorder for six weeks (KETADEP) http:\/\/clinicaltrials.gov\/show\/NCT01557712"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0102|cit102","unstructured":"NCT01558063 The antidepressant action of ketamine: brain chemistry http:\/\/clinicaltrials.gov\/show\/NCT01558063"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0103|cit103","unstructured":"NCT01613820 Combination of anticholinergic and glutamatergic effects in treatment-resistant major depressive disorder. A pilot study http:\/\/clinicaltrials.gov\/show\/NCT01613820"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0104|cit104","unstructured":"NCT01667926 Randomized, double-blind ketamine augmentation in chronically suicidal, treatment-resistant major depression http:\/\/clinicaltrials.gov\/show\/NCT01667926"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0105|cit105","unstructured":"NCT01684163 Phase 2, double-blind, placebo controlled, randomized withdrawal, parallel efficacy and safety study of GLYX-13 in subjects with inadequate\/partial response to antidepressants during the current episode of major depressive disorder http:\/\/clinicaltrials.gov\/show\/NCT01684163"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0106|cit106","unstructured":"NCT01700829 Ketamine vs. midazolam: testing rapid relief of suicide risk in depression http:\/\/clinicaltrials.gov\/show\/NCT01700829"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0107|cit107","unstructured":"NCT01703039 Riluzole augmentation pilot in depression (RAPID) trial http:\/\/clinicaltrials.gov\/show\/NCT01703039"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0108|cit108","unstructured":"NCT01868802 Ketamine for treatment-resistant depression: a multicentric clinical trial in Mexican population http:\/\/clinicaltrials.gov\/show\/NCT01868802"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0109|cit109","unstructured":"NCT01880593 Ketamine plus lithium as a novel pharmacotherapeutic strategy in treatment-resistant depression http:\/\/clinicaltrials.gov\/show\/NCT01880593"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0110|cit110","unstructured":"NCT01881763 Comparing therapeutic efficacy and cognitive side effects of electroconvulsive therapy (ECT) using ketamine versus methohexital anesthesia http:\/\/clinicaltrials.gov\/show\/NCT01881763"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0111|cit111","unstructured":"NCT01882829 Targeting the NMDA glutamate receptor as novel antidepressant strategy: a pilot clinical trial of nuedexta in treatment-resistant major depression http:\/\/clinicaltrials.gov\/show\/NCT01882829"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0112|cit112","unstructured":"NCT01887990 Treatment of suicidal ideation with intravenous ketamine infusion http:\/\/clinicaltrials.gov\/show\/NCT01887990"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0113|cit113","unstructured":"NCT01902004 Treatment of geriatric depression with mild cognitive impairment: a double-blind placebo-controlled trial of namenda (memantine) augmentation of lexapro (escitalopram) in depressed patients at least 60 years of age http:\/\/clinicaltrials.gov\/show\/NCT01902004"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0114|cit114","unstructured":"NCT01920555 Double-blind, placebo-controlled trial of ketamine therapy in treatment-resistant depression (TRD) http:\/\/clinicaltrials.gov\/show\/NCT01920555"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0115|cit115","unstructured":"NCT01935115 A prospective randomized double blinded control trial using ketamine or propofol anesthesia for electroconvulsive therapy: improving treatment-resistant depression http:\/\/clinicaltrials.gov\/show\/NCT01935115"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0116|cit116","unstructured":"NCT01944293 Ketamine vs. midazolam in bipolar depression http:\/\/clinicaltrials.gov\/show\/NCT01944293"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0117|cit117","unstructured":"NCT01945047 Phase 2 optimization of the antidepressant action of ketamine in treatment-resistant depression and investigations on its mechanism of action http:\/\/clinicaltrials.gov\/show\/NCT01945047"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0118|cit118","unstructured":"NCT01957410 An open-label and double-blind study to investigate evoked potentials as markers of ketamine-induced cortical plasticity in subjects with major depressive disorder http:\/\/clinicaltrials.gov\/show\/NCT01957410"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0119|cit119","unstructured":"NCT02012335 Ketamine use in electroconvulsive therapy: clinical, cognitives and neurotrophic outcomes http:\/\/clinicaltrials.gov\/show\/NCT02012335"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0120|cit120","unstructured":"NCT02014363 Double blind, non-inferiority study to evaluate the antidepressant activity of ETS6103 compared with amitriptyline in the treatment of major depressive disorder (MDD) in patients who have an unsatisfactory response to selective serotonin re-uptake Inhibitors (SSRIs) http:\/\/clinicaltrials.gov\/show\/NCT02014363"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0121|cit121","unstructured":"NCT02037503 Effect of oral ketamine treatment on suicidal ideation and drug resistant major depression, a clinical and fMRI study http:\/\/clinicaltrials.gov\/show\/NCT02037503"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0122|cit122","unstructured":"NCT02067793 Phase 2, randomized, double-blind, multiple-dose level, placebo controlled, single intravenous dose, parallel efficacy and safety study of NRX-1074 in subjects with major depressive disorder http:\/\/clinicaltrials.gov\/show\/NCT02067793"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0123|cit123","unstructured":"NCT02106325 A randomized, double-blinded controlled trial of an N-methyl D-aspartate antagonist as a rapidly-acting antidepressant in depressed emergency department patients http:\/\/clinicaltrials.gov\/show\/NCT02106325"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0124|cit124","unstructured":"NCT02139540 Nitrous oxide as treatment for major depression - a pilot study http:\/\/clinicaltrials.gov\/show\/NCT02139540"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0125|cit125","unstructured":"NCT02153502 A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deuterium modified dextromethorphan hydrobromide\/quinidine sulfate) as an adjunctive therapy in patients with Major depressive disorder with an inadequate response to antidepressant treatment http:\/\/clinicaltrials.gov\/show\/NCT02153502"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0126|cit126","unstructured":"NCT02267980 Effect of the addition of ketamine to sevoflurane anesthesia in electroconvulsive therapy http:\/\/clinicaltrials.gov\/show\/NCT02267980"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0127|cit127","unstructured":"NCT02295787 Intranasal ketamine for late-life depression and suicidal ideation http:\/\/clinicaltrials.gov\/show\/NCT02295787"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0128|cit128","unstructured":"NCT02299440 Evaluation of the effects of ketamine in the acute phase of suicidal ideation: a multicenter randomized double-blind trial http:\/\/clinicaltrials.gov\/show\/NCT02299440"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0129|cit129","unstructured":"NCT02305394 Effect of subanesthetic dose of ketamine combined with propofol on cognitive function in depressive patients undergoing electroconvulsive therapy - a randomized control double-blind clinical trial http:\/\/clinicaltrials.gov\/show\/NCT02305394"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0130|cit130","unstructured":"NTR3753 ECT and Memantine http:\/\/www.trialregister.nl\/trialreg\/admin\/rctview.asp?TC=3753"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0131|cit131","doi-asserted-by":"crossref","unstructured":"Quiroz JA Tamburri P Deptula D Banken L Beyer U Fontoura P The efficacy and safety of basimglurant as adjunctive therapy in major depression; a randomised, double-blind, placebo-controlled study [abstract] European Neuropsychopharmacology 2014 S468","DOI":"10.1016\/S0924-977X(14)70748-5"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"S387","DOI":"10.1016\/S0924-977X(14)70618-2","article-title":"Onset of efficacy of ketamine in treatment resistant depression: A double-blind, randomised, placebo-controlled, dose frequency [abstract]","volume":"Prfoceedings of","author":"Singh","year":"2014","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.biopsych.2012.05.003","article-title":"Ketamine for depression: where do we go from here?","volume":"72","author":"Aan Het Rot","year":"2012","journal-title":"Biol Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00001756-200303030-00018","article-title":"Ketamine alters neural processing of facial emotion recognition in healthy men: an fMRI study","volume":"14","author":"Abel","year":"2003","journal-title":"Neuroreport"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0135|cit135","first-page":"63","article-title":"Safety and effectiveness of intranasal administration of sedative medications (ketamine, midazolam, or sufentanil) for urgent brief pediatric dental procedures","volume":"40","author":"Abrams","year":"1993","journal-title":"Anesth Prog"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00213-013-3153-2","article-title":"Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR","volume":"230","author":"Akinfiresoye","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.2174\/1381612053764814","article-title":"AMPA receptor potentiators as novel antidepressants","volume":"11","author":"Alt","year":"2005","journal-title":"Curr Pharm Des"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0924-977X(95)00033-L","article-title":"Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression","volume":"5 Suppl","author":"Altamura","year":"1995","journal-title":"Eur Neuropsychopharmacol"},{"issue":"7066","key":"10.1002\/14651858.CD011612.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0140|cit140","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1980"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0141|cit141","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1987"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0142|cit142","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0143|cit143","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890423349","volume-title":"Diagnostic and Statistical Manual of Mental Disorders. 4th edition, Text Revision (DSM-IV-TR)","author":"American Psychiatric Association","year":"2000"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0144|cit144","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"issue":"3","key":"10.1002\/14651858.CD011612.pub2-BIB0145|cit145","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007954","article-title":"Antidepressants versus placebo for depression in primary care","author":"Arroll","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7454","key":"10.1002\/14651858.CD011612.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature10130","article-title":"NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses","volume":"475","author":"Autry","year":"2011","journal-title":"Nature"},{"issue":"9","key":"10.1002\/14651858.CD011612.pub2-BIB0148|cit148","first-page":"1428-34","article-title":"What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?","volume":"67","author":"Bandelow","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/mp.2011.47","article-title":"Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice","volume":"16","author":"Beurel","year":"2011","journal-title":"Mol Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00004850-199510030-00008","article-title":"Benzodiazepines for depression? A review of the literature","volume":"10","author":"Birkenhager","year":"1995","journal-title":"Int Clin Psychopharmacol"},{"issue":"33","key":"10.1002\/14651858.CD011612.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"1-56","DOI":"10.3310\/hta5330","article-title":"Subgroup analyses in randomized controlled trials: quantifying the risks of false-positives and false-negatives","volume":"5","author":"Brookes","year":"2001","journal-title":"Health Technology Assessment"},{"issue":"3","key":"10.1002\/14651858.CD011612.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jclinepi.2003.08.009","article-title":"Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test","volume":"57","author":"Brookes","year":"2004","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3389\/fphar.2013.00161","article-title":"Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants","volume":"4","author":"Browne","year":"2013","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1002\/14651858.CD011612.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/2045125313507739","article-title":"Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy","volume":"4","author":"Caddy","year":"2014","journal-title":"Therapeutic Advances in Psychopharmacology"},{"issue":"9665","key":"10.1002\/14651858.CD011612.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"746-58","DOI":"10.1016\/S0140-6736(09)60046-5","article-title":"Efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis","volume":"373","author":"Cipriani","year":"2009","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD011612.pub2-BIB0156|cit156","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006533.pub2","article-title":"Duloxetine versus other anti-depressive agents for depression","author":"Cipriani","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/0006-2952(74)90377-3","article-title":"Inhibition of mammalian brain acetylcholinesterase by ketamine","volume":"23","author":"Cohen","year":"1974","journal-title":"Biochem Pharmacol"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1192\/bjp.113.504.1237","article-title":"The biochemistry of affective disorders","volume":"113","author":"Coppen","year":"1967","journal-title":"Br J Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/hup.2475","article-title":"The use of ketamine as an antidepressant: a systematic review and meta-analysis","volume":"30","author":"Coyle","year":"2015","journal-title":"Human Psychopharmacology"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1017\/CBO9781139136341.041","article-title":"Suicide and depression","volume-title":"Essentials of Global Mental Health","author":"Leo","year":"2014"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1176\/appi.ajp.2011.09111607","article-title":"Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study","volume":"168","author":"Deschwanden","year":"2011","journal-title":"Am J Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2165\/00019053-200725010-00003","article-title":"Reducing the societal burden of depression: a review of economic costs, quality of care and effects of treatment","volume":"25","author":"Donohue","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0163|cit163","first-page":"259","article-title":"Depression","volume-title":"Handbook of Assessment and Treatment Planning for Psychological Disorders","author":"Dozois","year":"2004"},{"issue":"7109","key":"10.1002\/14651858.CD011612.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"629-34","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD011612.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"140-9","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving crossover trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD011612.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"57-63","DOI":"10.1001\/archpsyc.1972.01750190059011","article-title":"Diagnostic criteria for use in psychiatric research","volume":"26","author":"Feighner","year":"1972","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011612.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"72-6","DOI":"10.1093\/ije\/31.1.72","article-title":"An empirical study of summary effect measures in meta-analyses","volume":"31","author":"Furukawa","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD011612.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"49-52","DOI":"10.1097\/00004850-200501000-00010","article-title":"Imputing response rates from means and standard deviations in meta-analysis","volume":"20","author":"Furukawa","year":"2005","journal-title":"International Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD011612.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"7-10","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD011612.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"468-70","DOI":"10.1001\/jama.297.5.468-b","article-title":"Association between unreported outcomes and effect size estimates in Cochrane meta-analyses","volume":"297","author":"Furukawa","year":"2007","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD011612.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"531-4","DOI":"10.1097\/JCP.0b013e31814f30b1","article-title":"Evidence-based guidelines for interpretation of the Hamilton Rating Scale for Depression","volume":"27","author":"Furukawa","year":"2007","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0172|cit172","unstructured":"McMaster University (developed by Evidence Prime, Inc.) GRADEproGDT: GRADEpro Guideline Development Tool [www.guidelinedevelopment.org] 2015"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0173|cit173","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"issue":"7132","key":"10.1002\/14651858.CD011612.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"690-3","DOI":"10.1136\/bmj.316.7132.690","article-title":"Interpreting treatment effects in randomised trials","volume":"316","author":"Guyatt","year":"1998","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/j.2051-5545.2010.tb00298.x","article-title":"Pathophysiology of depression: do we have any solid evidence of interest to clinicians?","volume":"9","author":"Hasler","year":"2010","journal-title":"World Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD011612.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1176\/appi.ajp.2010.09070994","article-title":"Effect of acute psychological stress on prefrontal GABA concentration determined by proton magnetic resonance spectroscopy","volume":"167","author":"Hasler","year":"2010","journal-title":"Am J Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/S0140-6736(09)60372-X","article-title":"Suicide","volume":"373","author":"Hawton","year":"2009","journal-title":"Lancet"},{"issue":"7414","key":"10.1002\/14651858.CD011612.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"557-60","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0180|cit180","unstructured":"Higgins JPT Altman DG Sterne JAC Chapter 8: Assessing risk of bias in included studies In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0181|cit181","unstructured":"Higgins JPT Deeks JJ Altman DG Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. 2011"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0182|cit182","unstructured":"Higgins JPT Deeks JJ Chapter 7: Selecting studies and collecting data In Higgins JPT, Green S (editors),Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0183|cit183","first-page":"4","article-title":"History and evolution of the monoamine hypothesis of depression","volume":"61 Suppl 6","author":"Hirschfeld","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"11496","DOI":"10.1523\/JNEUROSCI.2213-07.2007","article-title":"NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons","volume":"27","author":"Homayoun","year":"2007","journal-title":"J Neurosci"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1176\/appi.ajp.2012.12040531","article-title":"Synaptic mechanisms underlying rapid antidepressant action of ketamine","volume":"169","author":"Kavalali","year":"2012","journal-title":"Am J Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1517\/14728222.9.1.153","article-title":"GABA and glutamate systems as therapeutic targets in depression and mood disorders","volume":"9","author":"Kendell","year":"2005","journal-title":"Expert Opin Ther Targets"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1001\/jama.289.23.3095","article-title":"The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)","volume":"289","author":"Kessler","year":"2003","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/archpsyc.62.6.593","article-title":"Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/bja\/42.10.875","article-title":"Clinical studies of induction agents. XXXVI: Ketamine","volume":"42","author":"Knox","year":"1970","journal-title":"Br J Anaesth"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bbr.2011.05.035","article-title":"Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression","volume":"224","author":"Koike","year":"2011","journal-title":"Behav Brain Res"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/0091-3057(95)00155-P","article-title":"Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715)","volume":"52","author":"Layer","year":"1995","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.biopsych.2007.05.028","article-title":"Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors","volume":"63","author":"Maeng","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/11599770-000000000-00000","article-title":"Ketamine for treatment-resistant unipolar depression: current evidence","volume":"26","author":"Mathew","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1017\/S0033291714001603","article-title":"A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes","volume":"45","author":"McGirr","year":"2015","journal-title":"Psychological Medicine"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","article-title":"Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex","volume":"17","author":"Moghaddam","year":"1997","journal-title":"J Neurosci"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"382-9","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/BF02246210","article-title":"Repeated ketamine administration produces up-regulation of muscarinic acetylcholine receptors in the forebrain, and reduces behavioral sensitivity to scopolamine in mice","volume":"117","author":"Morita","year":"1995","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1600-0773.1993.tb01351.x","article-title":"Potential antidepressive properties of amantadine, memantine and bifemelane","volume":"72","author":"Moryl","year":"1993","journal-title":"Pharmacol Toxicol"},{"issue":"3","key":"10.1002\/14651858.CD011612.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"255-60","DOI":"10.1016\/S0165-0327(02)00120-9","article-title":"Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS)","volume":"77","author":"Muller","year":"2003","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.jpsychires.2013.03.008","article-title":"Ketamine regulates the presynaptic release machinery in the hippocampus","volume":"47","author":"Muller","year":"2013","journal-title":"J Psychiatr Res"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jad.2013.11.014","article-title":"A review of ketamine in affective disorders: Current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action","volume":"156","author":"Naughton","year":"2014","journal-title":"J Affect Disord"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jad.2013.11.014","article-title":"A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action","volume":"156","author":"Naughton","year":"2014","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0205|cit205","unstructured":"National Institute for Health and Clinical Excellence Depression in adults: The treatment and management of depression in adults (CG90) http:\/\/publications.nice.org.uk\/depression-in-adults-cg90 2009"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(94)90516-9","article-title":"Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression","volume":"263","author":"Papp","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0014-2999(96)00675-9","article-title":"Antidepressant-like effects of 1-aminocyclopropanecarboxylic acid and D-cycloserine in an animal model of depression","volume":"316","author":"Papp","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0165-0327(84)90018-1","article-title":"Plasma GABA levels in psychiatric illness","volume":"6","author":"Petty","year":"1984","journal-title":"J Affect Disord"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/da.22253","article-title":"Effects of ketamine on explicit and implicit suicidal cognition: A randomized controlled trial in treatment-resistant depression","volume":"31","author":"Price","year":"2014","journal-title":"Depression and Anxiety"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0028-3908(96)00157-8","article-title":"Antidepressant-like effects of a partial agonist at strychnine-insensitive glycine receptors and a competitive NMDA receptor antagonist","volume":"36","author":"Przegalinski","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1124\/mi.4.5.6","article-title":"Molecular effects of lithium","volume":"4","author":"Quiroz","year":"2004","journal-title":"Mol Interv"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1176\/appi.ajp.162.6.1171","article-title":"Quality-of-life impairment in depressive and anxiety disorders","volume":"162","author":"Rapaport","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/BF03011442","article-title":"Ketamine: an update on the first twenty-five years of clinical experience","volume":"36","author":"Reich","year":"1989","journal-title":"Can J Anaesth"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0214|cit214","unstructured":"Rendell JM Shuttleworth C Amit BH Hawton K Diamond P McShane R Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0215|cit215","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/sj.mp.4001949","article-title":"Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies","volume":"12","author":"Ruhe","year":"2007","journal-title":"Mol Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/npp.2010.24","article-title":"Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine","volume":"35","author":"Salvadore","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0028-3908(81)90015-0","article-title":"Properties of the optical isomers and metabolites of ketamine on the high affinity transport and catabolism of monoamines","volume":"20","author":"Smith","year":"1981","journal-title":"Neuropharmacology"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/0028-3908(87)90084-0","article-title":"Properties of the interaction between ketamine and opiate binding sites in vivo and in vitro","volume":"26","author":"Smith","year":"1987","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1002\/14651858.CD011612.pub2-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"773-82","DOI":"10.1001\/archpsyc.1978.01770300115013","article-title":"Research diagnostic criteria: rationale and reliability","volume":"35","author":"Spitzer","year":"1978","journal-title":"Archives General Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD011612.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"1119-29","DOI":"10.1016\/S0895-4356(00)00242-0","article-title":"Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature","volume":"53","author":"Sterne","year":"2000","journal-title":"Journal of Clinical Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD011612.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"1051-63","DOI":"10.1017\/S0033291797005205","article-title":"Symptom profiles of depression among general medical service users compared with specialty mental health service users","volume":"27","author":"Suh","year":"1997","journal-title":"Psychological Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011612.pub2-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3109\/09638230903469269","article-title":"Systematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD)","volume":"19","author":"Thomas","year":"2010","journal-title":"Journal of Mental Health"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.pscychresns.2010.10.009","article-title":"The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS","volume":"191","author":"Valentine","year":"2011","journal-title":"Psychiatry Res"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0924-977X(96)00039-9","article-title":"Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG)","volume":"7","author":"Vollenweider","year":"1997","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/sj.bjp.0705942","article-title":"Intravenous anaesthetics inhibit nicotinic acetylcholine receptor-mediated currents and Ca2+ transients in rat intracardiac ganglion neurons","volume":"144","author":"Weber","year":"2005","journal-title":"Br J Pharmacol"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0227|cit227","volume-title":"The ICD-10 Classification of Mental and Behavioural Disorders","author":"World Health Organization (WHO)","year":"1992"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0228|cit228","volume-title":"International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10)","author":"World Health Organization","year":"2008"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0229|cit229","volume-title":"The global burden of disease: 2004 update","author":"World Health Organization (WHO)","year":"2008"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0230|cit230","unstructured":"World Health Organization (WHO) Sixty-fifth World Health Assembly: daily notes on proceedings Geneva World Health Organization 2012"},{"key":"10.1002\/14651858.CD011612.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s11126-012-9208-4","article-title":"Lamotrigine in the treatment of unipolar depression with and without comorbidities: a literature review","volume":"83","author":"Zavodnick","year":"2012","journal-title":"Psychiatric Quarterly"},{"issue":"7","key":"10.1002\/14651858.CD011612.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.euroneuro.2013.08.004","article-title":"A proposal for an updated neuropsychopharmacological nomenclature","volume":"24","author":"Zohar","year":"2014","journal-title":"Eur Neuropsychopharmaco"}],"updated-by":[{"DOI":"10.1002\/14651858.cd011612.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T00:00:00Z","timestamp":1631404800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD011612.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T04:50:33Z","timestamp":1653195033000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD011612.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Common Mental Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,9,23]]},"references-count":232,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011612.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD011612.pub3","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,23]]}}}